Platelets Activation in Patients Undergoing PTCA and Their Responsiveness After in vitro Stimulation

We evaluated expression of platelet activation markers in blood samples of 15 patients who underwent percutaneous transluminal coronary angioplasty (PTCA) by flow cytometry. Analysis was performed before the beginning of PTCA, during initial coronary angiography and after the end of PTCA or after a...

Full description

Bibliographic Details
Main Authors: Martina Loudová, Jan Krejsek
Format: Article
Language:English
Published: Karolinum Press 2003-01-01
Series:Acta Medica
Subjects:
Online Access:https://actamedica.lfhk.cuni.cz/46/4/0183/
id doaj-fb12c4a654f746e9af3fea2973b82531
record_format Article
spelling doaj-fb12c4a654f746e9af3fea2973b825312020-11-24T22:00:02ZengKarolinum PressActa Medica1211-42861805-96942003-01-0146418318810.14712/18059694.2019.31Platelets Activation in Patients Undergoing PTCA and Their Responsiveness After in vitro StimulationMartina Loudová0Jan Krejsek1Charles University in Prague, Faculty of Medicine in Hradec Králové, Department of Clinical Immunology and Allergology, Hradec Králové, Czech RepublicCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Clinical Immunology and Allergology, Hradec Králové, Czech RepublicWe evaluated expression of platelet activation markers in blood samples of 15 patients who underwent percutaneous transluminal coronary angioplasty (PTCA) by flow cytometry. Analysis was performed before the beginning of PTCA, during initial coronary angiography and after the end of PTCA or after a stent placement, respectively. We evaluated platelet-derived microparticles, platelet-leukocyte aggregates, platelet aggregates and a membrane expression of CD62P and CD63 molecules. Responsiveness of platelets to the activation in vitro with thrombin-receptor activating protein – 6 (TRAP-6) was tested simultaneously. Statistically significant differences between patient samples were found only in the expression of the activation markers CD62P (before PTCA 0.22 %, during 0.39 %, after 0.67 %), CD63 (0.26 %/ 0.45 %/ 0.85 %) and platelet-leukocyte aggregates (13.57 %/ 18.39 %/ 23.63 %).In the same group the expression of all constitutive membrane markers was statistically significantly decreased: in patients undergoing PTCA was the expression of CD9:87.98 % (in comparison with control group 94.98 %), CD31: 87.10 % (92.78 %), CD36: 87.37 % (90.98 %), CD41: 88.09 % (95.62 %), CD42a: 88.54 % (94.98 %), CD42a: 88.31 % (94.13 %).https://actamedica.lfhk.cuni.cz/46/4/0183/PlateletsActivation markersAngioplastyFlow cytometryPlatelet activation in vitro
collection DOAJ
language English
format Article
sources DOAJ
author Martina Loudová
Jan Krejsek
spellingShingle Martina Loudová
Jan Krejsek
Platelets Activation in Patients Undergoing PTCA and Their Responsiveness After in vitro Stimulation
Acta Medica
Platelets
Activation markers
Angioplasty
Flow cytometry
Platelet activation in vitro
author_facet Martina Loudová
Jan Krejsek
author_sort Martina Loudová
title Platelets Activation in Patients Undergoing PTCA and Their Responsiveness After in vitro Stimulation
title_short Platelets Activation in Patients Undergoing PTCA and Their Responsiveness After in vitro Stimulation
title_full Platelets Activation in Patients Undergoing PTCA and Their Responsiveness After in vitro Stimulation
title_fullStr Platelets Activation in Patients Undergoing PTCA and Their Responsiveness After in vitro Stimulation
title_full_unstemmed Platelets Activation in Patients Undergoing PTCA and Their Responsiveness After in vitro Stimulation
title_sort platelets activation in patients undergoing ptca and their responsiveness after in vitro stimulation
publisher Karolinum Press
series Acta Medica
issn 1211-4286
1805-9694
publishDate 2003-01-01
description We evaluated expression of platelet activation markers in blood samples of 15 patients who underwent percutaneous transluminal coronary angioplasty (PTCA) by flow cytometry. Analysis was performed before the beginning of PTCA, during initial coronary angiography and after the end of PTCA or after a stent placement, respectively. We evaluated platelet-derived microparticles, platelet-leukocyte aggregates, platelet aggregates and a membrane expression of CD62P and CD63 molecules. Responsiveness of platelets to the activation in vitro with thrombin-receptor activating protein – 6 (TRAP-6) was tested simultaneously. Statistically significant differences between patient samples were found only in the expression of the activation markers CD62P (before PTCA 0.22 %, during 0.39 %, after 0.67 %), CD63 (0.26 %/ 0.45 %/ 0.85 %) and platelet-leukocyte aggregates (13.57 %/ 18.39 %/ 23.63 %).In the same group the expression of all constitutive membrane markers was statistically significantly decreased: in patients undergoing PTCA was the expression of CD9:87.98 % (in comparison with control group 94.98 %), CD31: 87.10 % (92.78 %), CD36: 87.37 % (90.98 %), CD41: 88.09 % (95.62 %), CD42a: 88.54 % (94.98 %), CD42a: 88.31 % (94.13 %).
topic Platelets
Activation markers
Angioplasty
Flow cytometry
Platelet activation in vitro
url https://actamedica.lfhk.cuni.cz/46/4/0183/
work_keys_str_mv AT martinaloudova plateletsactivationinpatientsundergoingptcaandtheirresponsivenessafterinvitrostimulation
AT jankrejsek plateletsactivationinpatientsundergoingptcaandtheirresponsivenessafterinvitrostimulation
_version_ 1725845810286952448